Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy

Breast

Volumn 20, Issue 3, 2011, Pages 215-219

  Morgan, David A L ^a   Refalo, Nicholas A ^a   Cheung, Kwok Leung ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adjuvant tamoxifen; Strength of ER positivity; Survival

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 79957669554     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2010.11.004     Document Type: Article

References (17)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
2. Goldhirsch A., Ingle J.N., Gelber R.D., Thuerliman G., Senn H.J. Thres holds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
3. Elledge R.M., Green S., Pugh R., Allred D.C., Clark G.M., Hill J., et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a southwest oncology group study. Int J Cancer 2000, 89:111-117.
4. Pagani O., Gelber S., Simoncini E., Castiglione-Gertsch M., Price K.N., Gelber R.D., et al. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive node-positive breast cancer? International breast cancer study group trials VII and 12-93. Breast Cancer Res Treat 2009, 116:491-500.
5. Haybittle J.L., Blamey R.W., Elston C.W., Johnson J., Doyle P.J., Campbell F.C., et al. A prognostic index in primary breast cancer. Br J Cancer 1982, 45:361-366.
6. Todd J.H., Dowle C., Williams M.R., Elston C.W., Ellis I.O., Hinton C.P., et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987, 56:489-492.
7. Blamey R.W. Estimation of prognosis of the individual with primary breast cancer and its application. Scand J Surg 2002, 91:615-619.
8. McClelland R.A., Finlay P., Walker K.J., Nicholson D., Robertson J.F., Blamey R.W., et al. Automated quantitation of immunocytochemically localised oestrogen receptors in human breast cancer. Cancer Res 1990, 50:3545-3550.
9. Collins L.C., Botero M.L., Schnitt S.J. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005, 123:16-20.
10. Cheung K.L., Wong A.W.S., Parker H., Li V.W., Winterbottom L., Morgan D.A.L., et al. Pathological features of primary breast cancer in the elderly based on needle core biopsies - a large series from a single centre. Crit Rev Oncol/Hematol 2008, 67:263-267.
11. Kenny F.S., Willsher P.C., Gee J.M., Nicholson R., Pinder S.E., Ellis I.O., et al. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res Treat 2001, 65:135-144.
12. Goulding H., Pinder S., Cannon P., Pearson D., Nicholson R., Snead D., et al. A new immunohistochemical antibody for the assessment of oestrogen receptor status on routine formalin-fixed tissue samples. Human Pathology 1995, 26:291-294.
13. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thuerlimann B., Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 2005, 16:1569-1583.
14. Ogawa Y., Moriya T., Kato Y., Oguma M., Ikeda K., Takashima T., et al. Immuno-histochemical assessment for oestrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 2004, 11:267-275.
15. Thuerlimann B., Koeberle D., Senn H.-J. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. Eur J Cancer Vol 2007, 43:46-52.
16. Galea H., Blamey R.W., Elston C.E., Ellis I.O. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992, 22(3):207-219.
17. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.